Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

OBJECTIVE: Evaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS). DESIGN: A phase 2, multicenter, double-blind, randomized, placebo-controlled trial. SETTING: Outpatient and academic medical centers. PATIENT(S): One hundred fourteen women with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Snabes, Michael C., Ng, Juki, Li, Hong, Ali, Izna, Shebley, Mohamad, Schlaff, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310940/
https://www.ncbi.nlm.nih.gov/pubmed/37398623
http://dx.doi.org/10.1016/j.xfre.2023.02.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310940/
https://www.ncbi.nlm.nih.gov/pubmed/37398623
http://dx.doi.org/10.1016/j.xfre.2023.02.007

Ejemplares similares